Freenome 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Freenome went public on NASDAQ under ticker FRNM in July, raising approximately $310 million in gross proceeds.
- The FDA approved SimpleScreen CRC in July based on PREEMPT CRC, the largest prospective clinical validation study ever conducted for a blood-based colorectal cancer screening test; a pre-specified analysis adjusted to the U.S. Census showed 81.1% sensitivity at 90.4% specificity.
- Freenome reported top-line results for SimpleScreen CRC version 2: advanced precancerous lesion sensitivity increased from 30.5% to 41.9%, overall advanced precancerous lesion sensitivity increased from 13.7% to 18.2%, CRC sensitivity was 80.4%, and specificity was 90%.
- SimpleScreen Lung launched as an LDT; top-line results showed 85% sensitivity at 50% specificity, 82% sensitivity for stage 1 disease, and a 99.8% negative predictive value.
- Third-quarter 2026 revenue was $183.5 million, compared with $1 million in the third quarter of 2025; $182.5 million was license and collaboration revenue, including $180 million recognized following FDA approval of SimpleScreen CRC.
- Third-quarter 2026 operating expenses were $113 million, operating income was $70 million, and net income was $60.1 million, or $0.58 per share; third-quarter 2025 results were an operating loss of $65.3 million and a net loss of $64.5 million, or $0.95 per share.
- Third-quarter adjusted EBITDA was $117.9 million, compared with negative $56.3 million in the third quarter of 2025; free cash flow was $35.7 million, compared with negative $44.8 million, and included Abbott’s $100 million milestone payment.
- Freenome ended the third quarter with approximately $430 million in cash, cash equivalents, and marketable securities. It has received $242.2 million of the Abbott agreement’s up to $885 million in potential value.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, and thank you for standing by. Welcome to Freenome's third quarter 2026 earnings conference call. All participants will be able to listen only until the question-and-answer portion of this call. During the question-and-answer session, you will be able to ask your question by pressing star 11 on your touchtone phone. This call is being recorded by Freenome, with the exception of any participant's questions asked during the question-and-answer session. The entire call, including the question-and-answer session, is material copyrighted by Freenome. It cannot be recorded, rebroadcast without Freenome's express written permission. I would now like to introduce Mr. Bill Taggart, Director of Corporate Communications.
Good afternoon, and thank you for joining us. With me today are Aaron Elliott, Chief Executive Officer, Riley Ennis, Co-Founder and Chief Product Officer, and Linh Le, Chief Financial Officer. They will provide opening remarks, and following their comments, we will take your questions. Before we begin, please note that this call will include forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please refer to our most recent SEC filings for important risk factors that could cause our actual performance and results to materially differ from those expressed or implied in these forward-looking statements. Any forward-looking statements made on this call represent our views only as of today, and we disclaim any obligation to update any forward-looking statements. During this call, we will refer to certain non-GAAP financial measures, including non-GAAP net income, adjusted EBITDA, and free cash flow.
These non-GAAP measures should be considered in addition to, and not as a substitute for or superior to, our results prepared in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are included in our earnings press release issued today, which is available in the Investors section of our website at investors.freenome.com. Now, let me hand it to Aaron.
All right. Good afternoon, everybody. Thank you for joining our first earnings call as a public company. Today, we are really proud to introduce Freenome and share with you how we are working to bring our AI-enabled cancer screening platform to millions of patients. We really look forward to establishing an ongoing dialogue with the investment community as we execute on this mission. In July, we achieved a major milestone by going public on the Nasdaq under the ticker FRNM, raising approximately $310 million in gross proceeds. This couldn't have been possible without our incredible team, our clinical and commercial partners, the patients in our clinical studies, and the ongoing support of our shareholders. As we begin this new chapter as a public company, we are focused on building out our commercial infrastructure and advancing our broad product pipeline.
We are incredibly excited about the potential of our technology to truly transform the landscape of cancer screening. Now, since some of you are getting to know Freenome for the first time, I want to start with just a brief overview of who we are. We were founded in 2014 on a pretty simple premise, that the traditional approach to cancer screening is highly inefficient. Today's testing options are fragmented and burdensome, requiring patients to navigate completely different processes for different cancers. As a result, a large percentage of eligible people never get screened at all. We've turned this premise into our mission, to make early detection simple, accessible, and affordable so cancer can be caught at its earliest, most treatable stages.
Over the past decade, we've built a proprietary AI-driven multiomics discovery platform that has the ability to look at numerous biomarkers, including DNA and protein signatures, and incorporate the signals into our tests that are most informative for each cancer type. This platform serves as the foundation of our expanding portfolio of blood-based tests, which began with colorectal cancer, now extends to lung cancer, and will soon include other single and multi-cancer tests. By aligning screenings with an individual's risk profile, we believe we're uniquely positioned to scale AI-driven diagnostics, and we call this approach Personalized Cancer Detection. The data generated from these tests will really be key. Beginning with an FDA-approved reimbursed CRC test enables the collection of massive population-level molecular datasets and the establishment of a longitudinal relationship with the patient.
This data, we believe, will rapidly improve existing tests, confirm efficacy for other cancer types, and enable our potential expansion into broader disease areas beyond cancer. Now, it's been a pretty busy quarter for us. In addition to going public, we achieved numerous other milestones, including the FDA approval and commercial launch of our first test, SimpleScreen CRC, validation of an updated version of that test with improved performance, FDA Breakthrough Device Designation for our lung cancer test, and then most recently, the commercial launch of our SimpleScreen Lung LDT. In July, the FDA approved SimpleScreen CRC based on data from PREEMPT CRC, which was the largest prospective clinical validation study ever conducted for a blood-based colorectal cancer screening test. While colorectal cancer is highly preventable when caught early, nearly half of the 120 million eligible U.S. adults still remain unscreened.
We believe the simplicity and convenience of a blood test can really overcome traditional barriers to testing and dramatically increase screening adherence. The full results of PREEMPT CRC were published in JAMA in June 2025, and in a pre-specified analysis adjusted to the U.S. Census, SimpleScreen CRC detected colorectal cancer with 81.1% sensitivity at 90.4% specificity. Also in this quarter, we released top-line data for an updated version of SimpleScreen CRC. This is our version 2 test, and we were able to do it within one year of our first version, really demonstrating our ability to rapidly iterate on our technology and improve performance in detecting advanced precancerous lesions, which is really the most important. Riley will speak more to that here in a minute. Now, let's turn to commercial.
Our unique commercial model is to efficiently and cost-effectively scale SimpleScreen adoption by leveraging strategic partnerships, like the Abbott partnership for SimpleScreen CRC when it is ordered as a standalone test, and Roche for international kitting, combined with our internal sales team focused on targeting the approximately 600 health systems in the U.S. that are dedicated to increasing patient screening rates. This combination of partner-driven, bottoms-up awareness of SimpleScreen and top-down health system channel strategy is how we plan to scale our commercial foundation. Freenome maintains full U.S. commercial rights when SimpleScreen CRC is ordered in tandem with any other Freenome test where the patient meets criteria. That means we receive the full CRC reimbursement for those tests. This partnership structure was deliberate, as we anticipate the market will naturally shift towards risk-based multi-cancer screening from a simple blood draw. The data really supports this.
84% of the 120 million people eligible for CRC testing also qualify for another cancer screening test. Of course, you then get almost complete overlap when pairing with an asymptomatic MCED test. So we believe our Personalized Cancer Detection approach, layered on top of Abbott's reach into primary care with CRC, will really allow us to capture a disproportionate share of the value as multi-cancer screening becomes more common. Abbott holds exclusive U.S. commercialization rights for standalone CRC testing, backed by a licensing arrangement worth up to $885 million in potential payments to Freenome, tied to regulatory market access achievements and funding for joint research and development. To date, we have received $242.2 million of these payments, including most recently the $100 million milestone for CRC version one FDA approval.
Most importantly, to capitalize on the potential long-term success of the test and maintain financial upside, we also receive a 10% royalty on net sales once a 20% gross margin is achieved. Abbott provided many of the attributes that we were looking for in a partner, including one of the largest primary care sales channels, and importantly, the ability to reach the unscreened patient population with high efficiency. By scaling the SimpleScreen brand, Abbott effectively primes the market for our SimpleScreen commercial portfolio while generating the critical test data required to fuel our pipeline of next-generation AI-enabled cancer diagnostic tests. Abbott began marketing and selling SimpleScreen CRC on September 30th, integrating the test into its existing colorectal cancer screening portfolio and drawing on its established relationships with primary care providers and health systems nationwide.
We are only about a month into launch, so it is too early to really provide any specific volume guidance, but Abbott has trained its approximately 800-person sales force and begun the reach out to their 380,000 provider channel. At this stage of launch, the focus is really on EMR integrations, health system and provider engagement, putting in place the proper ordering workflows, and engaging payers on coverage. As of now, more than 2,000 clinical sites have requested blood collection kits, showing early interest, and we are watching this test conversion closely. We are currently working with Abbott to put together the commercial KPIs that we believe best track progress and future potential. We are highly encouraged by the recent momentum surrounding blood-based CRC testing, which has secured pivotal inclusions in both clinical guidelines and major insurance policies.
This progress is highlighted by the American Cancer Society's recent August update, which officially added SimpleScreen CRC as an approved screening option for average-risk adults. On the payer side, in addition to Medicare coverage, which set an initial price for SimpleScreen at $920, UnitedHealthcare led the industry by becoming the first major commercial insurer to establish coverage for blood-based CRC testing, really marking a crucial milestone towards widespread commercial acceptance. Carelon revised its clinical guidelines to cover SimpleScreen CRC as a medically necessary second-line option every three years for average-risk individuals. Cigna, most recently, with eviCore, one of the nation's largest specialty benefit managers, will implement a policy covering blood-based CRC screening across the 20 states that mandate alignment with ACS guidelines. Together, these developments represent a transformative shift for broader market access and patient adoption.
Separately, in September, HHS announced new appointments to the U.S. Preventive Services Task Force, really an encouraging step as it brings USPSTF back to full strength and enables it to resume its important work. We look forward to the future developments of this body. In addition to our commercial partnership with Abbott in the U.S., we have an exclusive license and option agreement with Roche to develop a kitted version of our multi-cancer test outside of the U.S. We believe this partnership can meaningfully expand global access to blood-based cancer screening over time, while Freenome retains ex-U.S. multi-cancer centralized testing rights. Beyond CRC, we recently reached a significant milestone by launching our SimpleScreen Lung test. This test is designed for adults age 50 to 80 with a minimum 20 pack-year smoking history who are currently not up to date with annual low-dose CT screening.
While nearly 15 million Americans qualify for lung cancer screening, fewer than 20% are actually up to date. We believe SimpleScreen Lung addresses this gap by offering physicians a practical and convenient screening option for their patients. Though we're just at the beginning of the launch, we're already engaged in encouraging discussions with health systems across the country. Our top-line results released last month demonstrated 85% sensitivity at 50% specificity, including 82% sensitivity for stage 1 disease and a 99.8% negative predictive value. Looking ahead, we are actively advancing enrollment for our PROACT Lung registrational study, which remains on track to support a future FDA submission. With that, I'd like to turn it over to Riley, who's going to walk you through the capabilities of our platform and how it's driving our long-term single cancer and multi-cancer test portfolio.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
